CD8+ T cells: An ineffective armor against prolonged COVID-19 in cancer patients

Oliver Van Oekelen; Samir Parekh

doi:10.1016/j.xcrm.2022.100695

CD8⁺ T cells: An ineffective armor against prolonged COVID-19 in cancer patients

Cell Rep Med. 2022 Jul 19;3(7):100695. doi: 10.1016/j.xcrm.2022.100695. Epub 2022 Jun 27.

Authors

Oliver Van Oekelen¹, Samir Parekh²

Affiliations

¹ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: [email protected].

Abstract

In a diverse cohort of cancer patients, Lyudovyk et al.¹ show that persistent COVID-19 infection is associated with weaker humoral responses and increased CD8⁺ T cell responses that are ineffective in clearing virus, particularly in patients receiving B cell-depleting therapies.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Comment

MeSH terms

CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
COVID-19*
Humans
Neoplasms* / complications

Abstract

Publication types

MeSH terms

Grants and funding